Analyst Conference Summaries

Biotechnology Investor Aids

Verastem
VSTM

conference date: March 14, 2024 10-K only

Verastem Cancer Therapy Should Get Traction, Raise Stock Price March 23, 2019 at Seeking Alpha

2024
Verastem
Q4 2023 press release
     
March 14, 2024      
2023
Verastem
Q4 2022 press release
Verastem
Q1 2023 press release
Verastem
Q2 2023 press release
Verastem
Q3 2023 press release
March 14, 2023 May 9, 2023 Aug. 8, 2023 No. 8, 2023
2022
Verastem
Q4 2021 press release
Verastem
Q1 2022 press release
Verastem
Q2 2022 press release
Verastem
Q3 2022 press release
March 28, 2022 May 9, 2022 August 8, 2022 Nov. 3, 2022
2021
Verastem
Q4 2020 press release
Verastem
Q1 2021 press release
Verastem
Q2 2021 press release
Verastem
Q3 2021 press release
March 18, 2021 May 11, 2021 Aug. 2, 2021 Nov. 4, 2021
2020
Verastem
Q4 2019
Verastem
Q1 2020
Verastem
Q2 2020
Verastem
Q3 2020 press release
Feb. 28, 2020 May 7, 2020 Aug. 10, 2020 Nov. 9, 2020
2019
Verastem
Q4 2018
Verastem
Q1 2019
Verastem
Q2 2019
Verastem
Q3 2019
March 12, 2019 May 9, 2019 August 1, 2019 Oct. 29, 2019
2018
March 13, 2018
May 3, 2018
August 8, 2018
Nov. 7, 2018

Verastem (VSTM) is a commercial-stage biotechnology company specializing in cancer therapies.

Verastem web site


 

Search

More Analyst Conference Pages:

 AGEN
 AGIO
 ALNY
 ALXN
 AMAT
 AMGN
 APRE
 ARWR
 BIIB
 CLDX
 CLSN
 CELG
 EPZM
 GILD
 GLYC
 ILMN
 INCY
 INO
 ISRG
 MCHP
 PLX
 REGN
 RNA
 SAGE
 SGEN
 TTPH
 VBLT
 VRTX
 XLRN
       

Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.

Copyright 2022 William P. Meyers